4,6-Di-0-(Aminoglycosyl)-1,3-Diaminocyclitol-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
    31.
    发明公开
    4,6-Di-0-(Aminoglycosyl)-1,3-Diaminocyclitol-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel 失效
    药物4,6-二 - O-(aminoglycosyl)-1,3- diaminocyclitol衍生物,它们的制备方法和含有这些化合物的。

    公开(公告)号:EP0007996A1

    公开(公告)日:1980-02-20

    申请号:EP79102220.5

    申请日:1979-07-02

    申请人: BAYER AG

    IPC分类号: C07H15/22 A61K31/70

    CPC分类号: C07D317/72 C07H15/236

    摘要: Aminoglykosidantibiotika der allgemeinen Formel
    wonn

    R 1 , R 2 , R 3 , R. und R 5 unabhängig voneinander Wasserstoff oder einen Rest der Formel
    enthalten, wobei
    A für

    R 6 für Wasserstoff, Triarylmethyl, Alkyl oder Acyl, oder 2 Reste R 6 gemeinsam Alkyliden, R 7 für Wasserstoff oder OR 6 , n 1 für 0, 1, 2 oder 3, n 2 für 0, 1, 2, 3, 4 oder 5 und n 3 , n. und n 5 unabhängig voneinander für 0, 1 oder 2 stehen, wobei die Summe aus n 1 , n 2 , n 3 und n 4 Werte von 1 bis 5 annimmt und die Gesamtzahl der OR 6 -Gruppen 2 bis 6 beträgt, und wenigstens einer der Reste R 1 , R 2 , R 3 , R 4 und R 5 nicht Wasserstoff ist, sind wirksamer und weniger toxisch als Aminoglykosidantibiotika, die diesen Rest nicht enthalten.

    摘要翻译: 通式氨基糖苷类抗生素其中R1 R2 R3,R4和R5独立地是氢或下式基团的包含其中A为-CH = CH-,[CH(2-N5) - (CH2OR6)N5 ] R 6表示氢,三芳基甲基,烷基或酰基,或者2个基团R 6一起亚烷基,R7是氢或OR 6,其中n1是0,1,2或3,n 2为0,1,2,3,4或5和n 3, N4和N5独立地为0,1或2,其中,N1,N2,N3和N4的值1-5接受并是OR6基团2到6的总数量之和,并且所述基团中的至少一个R1,R2 ,R3,R4和R5不是氢时,是更有效的,比不包含该基团的氨基糖苷类抗生素毒性较低。

    4-O-(AMINOGLYCOSYL)- OR 4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXY-5,5-DIFLUOROSTREPTAMINE DERIVATIVE AND PRODUCTION THEREOF
    34.
    发明授权
    4-O-(AMINOGLYCOSYL)- OR 4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXY-5,5-DIFLUOROSTREPTAMINE DERIVATIVE AND PRODUCTION THEREOF 失效
    4-O-(氨基糖基) - 或4,6-DI-O-(氨基糖基)-2,5-二脱氧-5,5-二氟右啡肽衍生物及其生产

    公开(公告)号:EP0546179B1

    公开(公告)日:1997-02-12

    申请号:EP91914768.6

    申请日:1991-08-22

    摘要: The invention provides 5-deoxy-5,5-difluoro derivatives of aminoglycoside antibiotics of neamine, kanamycin A, kanamycin B, gentamicin and seldomycin, each synthesized as a novel compound, and also 1-N-(α-hydroxy-φ-aminoalkanoyl) derivatives synthesized from the newly obtained 5-deoxy-5,5-difluorokanamycins A and B and analogs thereof. The 5-deoxy-5,5-difluoro derivatives thus obtained have antibacterial activities superior or substantially equivalent to those of the amino-glycoside antibiotics from which they are derived and further have a remarkably improved median lethal dose (LD50) when intravenously administered to mice and a remarkably reduced toxicity on mammals.

    摘要翻译: 本发明提供了分别作为新化合物合成的新胺,卡那霉素A,卡那霉素B,庆大霉素和司多霉素的氨基糖苷类抗生素的5-脱氧-5,5-二氟衍生物以及1-N-(α-羟基-φ-氨基链烷酰基 )由新获得的5-脱氧-5,5-二氟康卡霉素A和B及其类似物合成的衍生物。 如此获得的5-脱氧-5,5-二氟衍生物具有优于或基本等同于它们衍生自的氨基糖苷抗生素的抗菌活性,并且当对小鼠静脉内施用时还具有显着提高的半数致死剂量(LD50) 并且对哺乳动物的毒性显着降低。

    Macrolide antibiotics, process for their preparation, inter alia by fermentation, and pharmaceutical compositions containing them
    40.
    发明公开
    Macrolide antibiotics, process for their preparation, inter alia by fermentation, and pharmaceutical compositions containing them 失效
    大环内酯类抗生素,它们的制备方法,例如 通过发酵,和药物组合物含有它们。

    公开(公告)号:EP0033433A1

    公开(公告)日:1981-08-12

    申请号:EP80810346.9

    申请日:1980-11-10

    摘要: Disclosed are novel macrolide antibiotics of the general formula
    wherein R is H or OH; M is 0 or (H,OH); Z is the group of formula II,
    -CH 7 OH or groups which may be derived therefrom; A represents a double bond between carbon atoms of positions 12 and 13 or, together with the carbon atoms of positions 12 and 13, an oxirane ring. B represents a double bond between the carbon atoms of positions 10 and 11 or together with the carbon atoms of positions 10 and 11 the group -CH 2 -CH(O')-or-CH 2 -CH(O 2 )- and the non-toxic pharmaceutically acceptable ester and acid addition salts thereof.
    The novel antibiotic complex designated antibiotic AR-5 of the formula
    (falling within the scope of formula I), wherein R is hydrogen or hydroxy, and A represents a double bond or together with the carbon atoms of positions 12 and 13 an oxirane ring, can be produced by fermentation of a new species of the genus Micromonospora. which is Micromonospora Polytrota (e.g. NRR L 12066) The other compounds of formula I can be derived from the compounds of antibiotic AR-5 complex
    The compounds shown antibacterial activity. The gentamycine C complex is also produced by mic- r o monospora polytrota NRRL 12066

    摘要翻译: 本发明公开了通式 worin R是H或OH的新颖大环内酯抗生素; M为O或(H,OH); Z为式II基团的, -CH 2 OH或其中可衍生自那里基; 甲darstellt位置12的碳原子和13个或,与位置12和13的碳原子,在环氧乙烷环一起之间的双键。 乙darstellt位置10和碳原子11或连同位置10和11中的基团-CH 2 CH的碳原子之间的双键(Q <1>) - 或CH 2 CH(Q <2>) - 与无毒的药学上可接受的酯和酸加成盐。 新颖的抗生素复合物指定抗生素式的AR-5(下降式I的范围内),worin R是氢或羟基,且A darstellt双键或连同位置12和13的在碳原子上 环氧乙烷环,可通过属孢的一个新种的发酵来生产,小单孢所有这一切是Polytrota(例如NRRL 12066),我可以从抗生素AR-5复合物的化合物衍生的式的其他化合物。 示出抗菌活性的化合物。 因此,庆大霉素C复合物是由小单孢polytrota NRRL 12066产生